Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $170.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price lifted by Guggenheim from $135.00 to $170.00 in a report released on Monday, Marketbeat Ratings reports. Guggenheim currently has a buy rating on the stock.

Several other analysts have also recently commented on the company. B. Riley Financial raised their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft initiated coverage on Kymera Therapeutics in a research note on Thursday, July 30th. They set a “hold” rating and a $120.00 target price on the stock. Oppenheimer reissued an “outperform” rating and issued a $125.00 price target on shares of Kymera Therapeutics in a research note on Wednesday, August 5th. Mizuho raised their price target on Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Finally, TD Cowen raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.70.

Kymera Therapeutics Trading Down 0.4%

NASDAQ KYMR opened at $118.63 on Monday. Kymera Therapeutics has a 52 week low of $40.10 and a 52 week high of $130.05. The stock has a market cap of $9.86 billion, a price-to-earnings ratio of -36.61 and a beta of 1.96. The company has a 50-day moving average price of $113.96 and a two-hundred day moving average price of $94.49.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. Kymera Therapeutics’s revenue was up 465.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.95) earnings per share. As a group, equities research analysts expect that Kymera Therapeutics will post -3.78 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the completion of the transaction, the director directly owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. This trade represents a 6.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Noah Goodman sold 3,389 shares of Kymera Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total value of $387,328.81. Following the transaction, the insider owned 47,179 shares in the company, valued at approximately $5,392,087.91. This trade represents a 6.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,587,629 shares of company stock valued at $386,183,782 over the last three months. 15.98% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter. GAMMA Investing LLC lifted its stake in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics during the fourth quarter valued at approximately $63,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.